BACKGROUND: Primary pigmented nodular adrenocortical disease causes the Cushing syndrome in children and young adults and is most frequently associated with the Carney complex. OBJECTIVE: To evaluate diagnostic tests for primary pigmented nodular adrenocortical disease. DESIGN: Retrospective cohort study. SETTING: Tertiary care center. PATIENTS: 21 patients with primary pigmented nodular adrenocortical disease. The control groups consisted of 9 patients with macronodular adrenocortical disease and 15 patients with primary unilateral adrenocortical disease (single adenomas). MEASUREMENTS: Clinical characteristics, radiologic imaging, and a 6-day Liddle test with determination of urinary free cortisol and 17-hydroxycorticosteroid excretion. RESULTS: Adrenal imaging and other tests were of limited value for the diagnosis of primary pigmented nodular adrenocortical disease. The Liddle test, however, distinguished patients with this disorder from those with other primary adrenocortical lesions. An increase of 50% or more in urinary free cortisol levels on day 6 of the Liddle test identified 9 of 13 patients (69.2% [95% CI, 46.6% to 91.8%]) with primary pigmented nodular adrenocortical disease, excluded all patients with macronodular adrenocortical disease, and was present in only 3 of the 15 patients with single adrenocortical adenomas (20% [CI, 0% to 40.2%]). An increase in urinary free cortisol excretion of 100% or more on day 6 of the Liddle test identified only patients with primary pigmented nodular adrenocortical disease. CONCLUSIONS: Patients with primary pigmented nodular adrenocortical disease responded to dexamethasone with a paradoxical increase in glucocorticoid excretion during the Liddle test. This feature distinguishes such patients from those who have the Cushing syndrome caused by other primary adrenal disorders and may lead to timely detection of the Carney complex (a potentially fatal disorder) in asymptomatic patients.
BACKGROUND:Primary pigmented nodular adrenocortical disease causes the Cushing syndrome in children and young adults and is most frequently associated with the Carney complex. OBJECTIVE: To evaluate diagnostic tests for primary pigmented nodular adrenocortical disease. DESIGN: Retrospective cohort study. SETTING: Tertiary care center. PATIENTS: 21 patients with primary pigmented nodular adrenocortical disease. The control groups consisted of 9 patients with macronodular adrenocortical disease and 15 patients with primary unilateral adrenocortical disease (single adenomas). MEASUREMENTS: Clinical characteristics, radiologic imaging, and a 6-day Liddle test with determination of urinary free cortisol and 17-hydroxycorticosteroid excretion. RESULTS: Adrenal imaging and other tests were of limited value for the diagnosis of primary pigmented nodular adrenocortical disease. The Liddle test, however, distinguished patients with this disorder from those with other primary adrenocortical lesions. An increase of 50% or more in urinary free cortisol levels on day 6 of the Liddle test identified 9 of 13 patients (69.2% [95% CI, 46.6% to 91.8%]) with primary pigmented nodular adrenocortical disease, excluded all patients with macronodular adrenocortical disease, and was present in only 3 of the 15 patients with single adrenocortical adenomas (20% [CI, 0% to 40.2%]). An increase in urinary free cortisol excretion of 100% or more on day 6 of the Liddle test identified only patients with primary pigmented nodular adrenocortical disease. CONCLUSIONS:Patients with primary pigmented nodular adrenocortical disease responded to dexamethasone with a paradoxical increase in glucocorticoid excretion during the Liddle test. This feature distinguishes such patients from those who have the Cushing syndrome caused by other primary adrenal disorders and may lead to timely detection of the Carney complex (a potentially fatal disorder) in asymptomatic patients.
Authors: Paul Byron Bandelin; Albert J Moreno; Homer Jess Lemar; Constantine A Stratakis; Thomas George Oliver Journal: J Clin Endocrinol Metab Date: 2008-08 Impact factor: 5.958
Authors: M Cignarelli; G Picca; M Campo; M Margaglione; A Marino; F Logoluso; F Giorgino Journal: J Endocrinol Invest Date: 2005-01 Impact factor: 4.256
Authors: Paraskevi Salpea; Anelia Horvath; Edra London; Fabio R Faucz; Annalisa Vetro; Isaac Levy; Evgenia Gourgari; Andrew Dauber; Ingrid A Holm; Patrick J Morrison; Margaret F Keil; Charalampos Lyssikatos; Eric D Smith; Marc A Sanidad; JoAnn C Kelly; Zunyan Dai; Philip Mowrey; Antonella Forlino; Orsetta Zuffardi; Constantine A Stratakis Journal: J Clin Endocrinol Metab Date: 2013-12-20 Impact factor: 5.958
Authors: Johannes Hofland; Wouter W de Herder; Lieke Derks; Leo J Hofland; Peter M van Koetsveld; Ronald R de Krijger; Francien H van Nederveen; Anelia Horvath; Constantine A Stratakis; Frank H de Jong; Richard A Feelders Journal: Eur J Endocrinol Date: 2012-12-10 Impact factor: 6.664
Authors: Isabelle Sahut-Barnola; Cyrille de Joussineau; Pierre Val; Sarah Lambert-Langlais; Christelle Damon; Anne-Marie Lefrançois-Martinez; Jean-Christophe Pointud; Geoffroy Marceau; Vincent Sapin; Frédérique Tissier; Bruno Ragazzon; Jérôme Bertherat; Lawrence S Kirschner; Constantine A Stratakis; Antoine Martinez Journal: PLoS Genet Date: 2010-06-10 Impact factor: 5.917
Authors: George N Zografos; Theodora Pappa; Spiros Avlonitis; Athina Markou; Dimosthenis T Chrysikos; Gregory Kaltsas; Chrysanthi Aggeli; George Piaditis Journal: J Med Case Rep Date: 2010-07-29